Search research articles
Contact Us
Filters
Showing results (271-280 of 336) with videos related to
Page
of 34
Sort By:
European Urology Open Science
|
November 24, 2025
Efficacy of Enfortumab Vedotin After Platinum Chemotherapy and Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the ARON-2EV Cohort
Ondrej Fiala, Francesco Grillone, Kazutoshi Fujita, et al.
Clinical & Experimental Metastasis
|
November 21, 2025
Time to metastasis as a prognostic factor in metastatic urothelial carcinoma: results from the ARON-2 study
Renate Pichler, Gerald Klinglmair, Kirstin Binz, et al.
Cancer Immunology, Immunotherapy : CII
|
May 9, 2025
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study
Camillo Porta, Francesco Massari, Tarek Taha, et al.
Targeted Oncology
|
May 5, 2024
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study)
Ondřej Fiala, Sebastiano Buti, Aristotelis Bamias, et al.
Journal of Clinical Pathology
|
November 4, 2020
MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma
Matteo Brunelli, Alessandro Tafuri, Luca Cima, et al.
Clinical Lung Cancer
|
March 20, 2019
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients
Alessio Cortellini, Rita Chiari, Biagio Ricciuti, et al.
Clinical & Experimental Metastasis
|
February 20, 2025
Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2<sup>EV</sup> study
Ondřej Fiala, Sebastiano Buti, Kazutoshi Fujita, et al.
Frontiers in Immunology
|
July 22, 2024
Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study
Martina Catalano, Sara Elena Rebuzzi, Marco Maruzzo, et al.
JAMA Network Open
|
November 27, 2023
Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab
Martina Catalano, Sara Elena Rebuzzi, Marco Maruzzo, et al.
Clinical Genitourinary Cancer
|
May 14, 2018
Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program
Giuseppe Procopio, Michele Prisciandaro, Roberto Iacovelli, et al.
Page
of 34
Search research articles
Search
Showing results (271-280 of 336) with videos related to
Sort By:
Page
of 34
European Urology Open Science
|
November 24, 2025
Efficacy of Enfortumab Vedotin After Platinum Chemotherapy and Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the ARON-2EV Cohort
Ondrej Fiala, Francesco Grillone, Kazutoshi Fujita, et al.
Clinical & Experimental Metastasis
|
November 21, 2025
Time to metastasis as a prognostic factor in metastatic urothelial carcinoma: results from the ARON-2 study
Renate Pichler, Gerald Klinglmair, Kirstin Binz, et al.
Cancer Immunology, Immunotherapy : CII
|
May 9, 2025
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study
Camillo Porta, Francesco Massari, Tarek Taha, et al.
Targeted Oncology
|
May 5, 2024
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study)
Ondřej Fiala, Sebastiano Buti, Aristotelis Bamias, et al.
Journal of Clinical Pathology
|
November 4, 2020
MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma
Matteo Brunelli, Alessandro Tafuri, Luca Cima, et al.
Clinical Lung Cancer
|
March 20, 2019
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients
Alessio Cortellini, Rita Chiari, Biagio Ricciuti, et al.
Clinical & Experimental Metastasis
|
February 20, 2025
Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2<sup>EV</sup> study
Ondřej Fiala, Sebastiano Buti, Kazutoshi Fujita, et al.
Frontiers in Immunology
|
July 22, 2024
Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study
Martina Catalano, Sara Elena Rebuzzi, Marco Maruzzo, et al.
JAMA Network Open
|
November 27, 2023
Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab
Martina Catalano, Sara Elena Rebuzzi, Marco Maruzzo, et al.
Clinical Genitourinary Cancer
|
May 14, 2018
Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program
Giuseppe Procopio, Michele Prisciandaro, Roberto Iacovelli, et al.
Page
of 34